Analyst Jonathan Chang from Leerink Partners reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) and keeping the price target at $2.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jonathan Chang’s rating is based on a combination of factors, including Adaptimmune Therapeutics’ recent financial performance and strategic developments. The company reported first-quarter 2025 revenues from Tecelra that were slightly below market expectations, although there was a noticeable increase from the previous quarter. Additionally, the number of authorized treatment centers has grown, indicating potential for future revenue growth.
Despite these positive signs, the company’s financial liquidity remains a concern, with ongoing exploration of strategic options to extend its operational runway. Furthermore, while there are promising developments in the pipeline, such as the anticipated BLA submission for lete-cel and potential commercial launches, these are expected to materialize in the longer term. As such, the Hold rating reflects a cautious stance, balancing current performance with future potential.
According to TipRanks, Chang is an analyst with an average return of -13.0% and a 28.10% success rate. Chang covers the Healthcare sector, focusing on stocks such as Zai Lab, Nanobiotix, and Xencor.
In another report released yesterday, Wells Fargo also maintained a Hold rating on the stock with a $1.00 price target.